Ignite Creation Date:
2025-12-25 @ 4:50 AM
Ignite Modification Date:
2025-12-26 @ 3:51 AM
Study NCT ID:
NCT00843518
Status:
COMPLETED
Last Update Posted:
2017-11-29
First Post:
2009-02-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.
Detailed Description:
The primary purpose of this study is to help answer the following research questions:
* Whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's Disease.
* The safety of this drug and any side effects that might be associated with it.
* How this drug compares to placebo.
During the 12-week period of this study, the participant will have an equal chance of receiving 1 of the 2 treatment groups: active drug or placebo.
* Whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's Disease.
* The safety of this drug and any side effects that might be associated with it.
* How this drug compares to placebo.
During the 12-week period of this study, the participant will have an equal chance of receiving 1 of the 2 treatment groups: active drug or placebo.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| H6N-MC-LEAQ | OTHER | Eli Lilly and Company | View |